This stock has the best risk/reward ratio that I can think of. 2 years ago the stock was priced at $5.00. After what smells like a concerted effert on the part of two ex-directors, numerous other accomplices, multiple lawsuits, what appears to be direct market manipulation, the market correction, tax selling, and Sept 11 the price of the stock is $0.13. But during that time, the management time has been able to acquire 5 new patents and a scientific team from the University of Georgetown as well as a $25 million equity line of credit at 100% of the market price.
The lawsuits are over, all in SPHC's benefit.
The recent levelness of the stock seems to indicate that the manipulators have run out of stock to sell.
Tax selling season is over.
There are now 6 patents instead of 1.
There is a scientific team were there wasn't one.
There is a laboratory where there weren't any.
Historically, penny stocks do quite well over the beginning part of the year.
Also, the premier patent on the drug Anticort is finished with the Phase 2 trials and the company is expecting results in January.
In short the price has been beaten down by every means possible and a upside swing potential is huge. |
